Accuray Inc. (NASDAQ:ARAY) shares were down 1.7% on Friday . The stock traded as low as $5.23 and last traded at $5.24, with a volume of 192,332 shares trading hands. The stock had previously closed at $5.33.

Several research analysts recently weighed in on ARAY shares. Zacks Investment Research raised Accuray from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Wednesday, March 30th. Morgan Stanley reaffirmed a “hold” rating on shares of Accuray in a research note on Wednesday, April 27th. Finally, Brean Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Accuray in a research note on Sunday, May 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Accuray currently has a consensus rating of “Hold” and an average target price of $8.58.

The company’s market capitalization is $433.75 million. The firm’s 50-day moving average price is $5.23 and its 200-day moving average price is $5.47.

Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, April 26th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. The company had revenue of $105.30 million for the quarter, compared to the consensus estimate of $102.79 million. During the same quarter last year, the business earned ($0.04) EPS. Accuray’s quarterly revenue was up 8.0% compared to the same quarter last year. Equities research analysts expect that Accuray Inc. will post ($0.27) earnings per share for the current fiscal year.

Other institutional investors have modified their holdings of the company. Russell Frank Co increased its position in shares of Accuray by 24.0% in the fourth quarter. Russell Frank Co now owns 1,028,628 shares of the company’s stock valued at $7,077,000 after buying an additional 198,874 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Accuray by 20.9% in the fourth quarter. Wells Fargo & Company MN now owns 1,656,069 shares of the company’s stock valued at $11,178,000 after buying an additional 286,458 shares during the last quarter. Lapides Asset Management LLC increased its position in shares of Accuray by 1.8% in the fourth quarter. Lapides Asset Management LLC now owns 2,149,500 shares of the company’s stock valued at $14,509,000 after buying an additional 38,600 shares during the last quarter. Finally, Boston Partners increased its position in shares of Accuray by 10.8% in the fourth quarter. Boston Partners now owns 4,272,040 shares of the company’s stock valued at $28,836,000 after buying an additional 417,568 shares during the last quarter.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.